Pharma Deals Review, Vol 2010, No 2 (2010)

Font Size:  Small  Medium  Large

GSK in Lung Drug Deal with Apeiron

Taskin Ahmed

Abstract


GlaxoSmithKline (GSK), a leader in the treatment of respiratory diseases, has obtained the rights to a Phase I enzyme biotherapeutic produced by Vienna-based Apeiron Biologics. The drug is in trials for the treatment of acute respiratory disease syndrome (ARDS) - a side effect associated with sepsis.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.